Signal integration, crosstalk mechanisms and networks in the function of inflammatory cytokines

Biochimica et Biophysica Acta - Molecular Cell Research

Volumn 1813, Issue 12, 2011, Pages 2165-2175

  Schmitz, M Lienhard ^a   Weber, Axel ^c   Roxlau, Thomas ^c   Gaestel, Matthias ^b   Kracht, Michael ^c  

^a JUSTUS LIEBIG UNIVERSITY   (Germany)

^b HANNOVER MEDICAL SCHOOL   (Germany)

^c JUSTUS LIEBIG UNIVERSITY GIESSEN   (Germany)

Author keywords

Cytokine signaling network; Feed forward loop; Feedback loop; IL 1; Inflammation; TNF

Indexed keywords

ANTINEOPLASTIC AGENT; CHEMOKINE; CYTOKINE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 1; INTERLEUKIN 1ALPHA; INTERLEUKIN 1BETA; INTERLEUKIN 33; INTERLEUKIN 6; MACROPHAGE MIGRATION INHIBITION FACTOR; TRANSFORMING GROWTH FACTOR BETA ACTIVATED KINASE 1; TUMOR NECROSIS FACTOR ALPHA;

CANCER COMBINATION CHEMOTHERAPY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; DIABETES MELLITUS; DRUG FEVER; DRUG TOLERABILITY; ENTERITIS; ENZYME ACTIVATION; ENZYME PHOSPHORYLATION; GOUT; HUMAN; HYPOTENSION; IMMUNE RESPONSE; INFLAMMATION; MATHEMATICAL MODEL; MELANOMA; MOLECULAR INTERACTION; MUCKLE WELLS SYNDROME; NAUSEA; NEGATIVE FEEDBACK; NONHUMAN; POSITIVE FEEDBACK; PRIORITY JOURNAL; PROTEIN FUNCTION; PSORIASIS; REVIEW; RHEUMATOID ARTHRITIS; SIGNAL PROCESSING; SIGNAL TRANSDUCTION; SOFT TISSUE SARCOMA; TREATMENT RESPONSE;

ANIMALS; CELL COMMUNICATION; CYTOKINES; HUMANS; INFLAMMATION; INFLAMMATION MEDIATORS; SIGNAL TRANSDUCTION;

EID: 82555167069     PISSN: 01674889     EISSN: 18792596     Source Type: Journal    
DOI: 10.1016/j.bbamcr.2011.06.019     Document Type: Review

References (161)

1. Abraham S.M., Clark A.R. Dual-specificity phosphatase 1: a critical regulator of innate immune responses. Biochem. Soc. Trans. 2006, 34:1018-1023.
2. Abraham S.M., Lawrence T., Kleiman A., Warden P., Medghalchi M., Tuckermann J., Saklatvala J., Clark A.R. Antiinflammatory effects of dexamethasone are partly dependent on induction of dual specificity phosphatase 1. J. Exp. Med. 2006, 203:1883-1889.
3. Agostini L., Martinon F., Burns K., McDermott M.F., Hawkins P.N., Tschopp J. NALP3 forms an IL-1beta-processing inflammasome with increased activity in Muckle-Wells autoinflammatory disorder. Immunity 2004, 20:319-325.
4. Aksentijevich I., Masters S.L., Ferguson P.J., Dancey P., Frenkel J., Royen-Kerkhoff A., Laxer R., Tedgard U., Cowen E.W., Pham T.H., Booty M., Estes J.D., Sandler N.G., Plass N., Stone D.L., Turner M.L., Hill S., Butman J.A., Schneider R., Babyn P., El Shanti H.I., Pope E., Barron K., Bing X., Laurence A., Lee C.C., Chapelle D., Clarke G.I., Ohson K., Nicholson M., Gadina M., Yang B., Korman B.D., Gregersen P.K., van Hagen P.M., Hak A.E., Huizing M., Rahman P., Douek D.C., Remmers E.F., Kastner D.L., Goldbach-Mansky R. An autoinflammatory disease with deficiency of the interleukin-1-receptor antagonist. N. Engl. J. Med. 2009, 360:2426-2437.
5. Alexopoulos L.G., Saez-Rodriguez J., Cosgrove B.D., Lauffenburger D.A., Sorger P.K. Networks inferred from biochemical data reveal profound differences in toll-like receptor and inflammatory signaling between normal and transformed hepatocytes. Mol. Cell. Proteomics 2010, 9:1849-1865.
6. Alonso-Ruiz A., Pijoan J.I., Ansuategui E., Urkaregi A., Calabozo M., Quintana A. Tumor necrosis factor alpha drugs in rheumatoid arthritis: systematic review and metaanalysis of efficacy and safety. BMC Musculoskelet. Disord. 2008, 9:52.
7. Anderson P. Post-transcriptional control of cytokine production. Nat. Immunol. 2008, 9:353-359.
8. Anderson P. Intrinsic mRNA stability helps compose the inflammatory symphony. Nat. Immunol. 2009, 10:233-234.
9. Auron P.E., Webb A.C., Rosenwasser L.J., Mucci S.F., Rich A., Wolff S.M., Dinarello C.A. Nucleotide sequence of human monocyte interleukin 1 precursor cDNA. Proc. Natl. Acad. Sci. U.S.A. 1984, 81:7907-7911.
10. Baruch K., Gur-Arie L., Nadler C., Koby S., Yerushalmi G., Ben-Neriah Y., Yogev O., Shaulian E., Guttman C., Zarivach R., Rosenshine I. Metalloprotease type III effectors that specifically cleave JNK and NF-kappaB. EMBO J. 2011, 30:221-231.
11. Bettermann K., Vucur M., Haybaeck J., Koppe C., Janssen J., Heymann F., Weber A., Weiskirchen R., Liedtke C., Gassler N., Muller M., de V.R., Wolf M.J., Boege Y., Seleznik G.M., Zeller N., Erny D., Fuchs T., Zoller S., Cairo S., Buendia M.A., Prinz M., Akira S., Tacke F., Heikenwalder M., Trautwein C., Luedde T. TAK1 suppresses a NEMO-dependent but NF-kappaB-independent pathway to liver cancer. Cancer Cell 2010, 17:481-496.
12. Bhoj V.G., Chen Z.J. Ubiquitylation in innate and adaptive immunity. Nature 2009, 458:430-437.
13. Boniface K., Bak-Jensen K.S., Li Y., Blumenschein W.M., McGeachy M.J., McClanahan T.K., McKenzie B.S., Kastelein R.A., Cua D.J., de Waal M.R. Prostaglandin E2 regulates Th17 cell differentiation and function through cyclic AMP and EP2/EP4 receptor signaling. J. Exp. Med. 2009, 206:535-548.
14. Bottero V., Kerur N., Sadagopan S., Patel K., Sharma-Walia N., Chandran B. Phosphorylation and polyubiquitination of transforming growth factor {beta}-activated kinase 1 are necessary for activation of NF-{kappa}B by the Kaposi's sarcoma-associated herpesvirus G protein-coupled receptor. J. Virol. 2011, 85:1980-1993.
15. Brook M., Tchen C.R., Santalucia T., McIlrath J., Arthur J.S., Saklatvala J., Clark A.R. Posttranslational regulation of tristetraprolin subcellular localization and protein stability by p38 mitogen-activated protein kinase and extracellular signal-regulated kinase pathways. Mol. Cell. Biol. 2006, 26:2408-2418.
16. Brooks J.W., Mizel S.B. Interleukin-1 signal transduction. Eur. Cytokine Netw. 1994, 5:547-561.
17. Brummelkamp T.R., Nijman S.M., Dirac A.M., Bernards R. Loss of the cylindromatosis tumour suppressor inhibits apoptosis by activating NF-kappaB. Nature 2003, 424:797-801.
18. Buchan J.R., Parker R. Eukaryotic stress granules: the ins and outs of translation. Mol. Cell 2009, 36:932-941.
19. Calvano S.E., Xiao W., Richards D.R., Felciano R.M., Baker H.V., Cho R.J., Chen R.O., Brownstein B.H., Cobb J.P., Tschoeke S.K., Miller-Graziano C., Moldawer L.L., Mindrinos M.N., Davis R.W., Tompkins R.G., Lowry S.F. A network-based analysis of systemic inflammation in humans. Nature 2005, 437:1032-1037.
20. Carballo E., Lai W.S., Blackshear P.J. Feedback inhibition of macrophage tumor necrosis factor-alpha production by tristetraprolin. Science 1998, 281:1001-1005.
21. Chen B.S., Yang S.K., Lan C.Y., Chuang Y.J. A systems biology approach to construct the gene regulatory network of systemic inflammation via microarray and databases mining. BMC Med. Genomics 2008, 1:46.
22. Chen G.Y., Nunez G. Sterile inflammation: sensing and reacting to damage. Nat. Rev. Immunol. 2010, 10:826-837.
23. Chew J., Biswas S., Shreeram S., Humaidi M., Wong E.T., Dhillion M.K., Teo H., Hazra A., Fang C.C., Lopez-Collazo E., Bulavin D.V., Tergaonkar V. WIP1 phosphatase is a negative regulator of NF-kappaB signalling. Nat. Cell Biol. 2009, 11:659-666.
24. Chi H., Barry S.P., Roth R.J., Wu J.J., Jones E.A., Bennett A.M., Flavell R.A. Dynamic regulation of pro- and anti-inflammatory cytokines by MAPK phosphatase 1 (MKP-1) in innate immune responses. Proc. Natl. Acad. Sci. U.S.A. 2006, 103:2274-2279.
25. Chi H., Flavell R.A. Acetylation of MKP-1 and the control of inflammation. Sci. Signal. 2008, 1:e44.
26. Chong H.C., Tan M.J., Philippe V., Tan S.H., Tan C.K., Ku C.W., Goh Y.Y., Wahli W., Michalik L., Tan N.S. Regulation of epithelial-mesenchymal IL-1 signaling by PPARbeta/delta is essential for skin homeostasis and wound healing. J. Cell Biol. 2009, 184:817-831.
27. Collison L.W., Workman C.J., Kuo T.T., Boyd K., Wang Y., Vignali K.M., Cross R., Sehy D., Blumberg R.S., Vignali D.A. The inhibitory cytokine IL-35 contributes to regulatory T-cell function. Nature 2007, 450:566-569.
28. Costa M.F., Said N.R., Zimmermann B. Drug-induced lupus due to anti-tumor necrosis factor alpha agents. Semin. Arthritis Rheum. 2008, 37:381-387.
29. Covert M.W., Leung T.H., Gaston J.E., Baltimore D. Achieving stability of lipopolysaccharide-induced NF-kappaB activation. Science 2005, 309:1854-1857.
30. Creaven P.J., Plager J.E., Dupere S., Huben R.P., Takita H., Mittelman A., Proefrock A. Phase I clinical trial of recombinant human tumor necrosis factor. Cancer Chemother. Pharmacol. 1987, 20:137-144.
31. Di Y., Li S., Wang L., Zhang Y., Dorf M.E. Homeostatic interactions between MEKK3 and TAK1 involved in NF-kappaB signaling. Cell. Signal. 2008, 20:705-713.
32. Dinarello C., Arend W., Sims J., Smith D., Blumberg H., O'Neill L., Goldbach-Mansky R., Pizarro T., Hoffman H., Bufler P., Nold M., Ghezzi P., Mantovani A., Garlanda C., Boraschi D., Rubartelli A., Netea M., van der Meer J., Joosten L., Mandrup-Poulsen T., Donath M., Lewis E., Pfeilschifter J., Martin M., Kracht M., Muehl H., Novick D., Lukic M., Conti B., Solinger A., Peyman K., van de Veerdonk F., Gabel C. IL-1 family nomenclature. Nat. Immunol. 2010, 11:973.
33. Dinarello C.A. Biologic basis for interleukin-1 in disease. Blood 1996, 87:2095-2147.
34. Dinarello C.A. An IL-1 family member requires caspase-1 processing and signals through the ST2 receptor. Immunity 2005, 23:461-462.
35. Dinarello C.A. Historical insights into cytokines. Eur. J. Immunol. 2007, 37(Suppl 1):S34-S45.
36. Dinarello C.A. Immunological and inflammatory functions of the interleukin-1 family. Annu. Rev. Immunol. 2009, 27:519-550.
37. Dinarello C.A. Interleukin-1beta and the autoinflammatory diseases. N. Engl. J. Med. 2009, 360:2467-2470.
38. Dinarello C.A. Anti-inflammatory agents: present and future. Cell 2010, 140:935-950.
39. Dinarello C.A. Interleukin-1 in the pathogenesis and treatment of inflammatory diseases. Blood 2011.
40. Dinarello C.A., Ikejima T., Warner S.J., Orencole S.F., Lonnemann G., Cannon J.G., Libby P. Interleukin 1 induces interleukin 1. I. Induction of circulating interleukin 1 in rabbits in vivo and in human mononuclear cells in vitro. J. Immunol. 1987, 139:1902-1910.
41. Economides A.N., Carpenter L.R., Rudge J.S., Wong V., Koehler-Stec E.M., Hartnett C., Pyles E.A., Xu X., Daly T.J., Young M.R., Fandl J.P., Lee F., Carver S., McNay J., Bailey K., Ramakanth S., Hutabarat R., Huang T.T., Radziejewski C., Yancopoulos G.D., Stahl N. Cytokine traps: multi-component, high-affinity blockers of cytokine action. Nat. Med. 2003, 9:47-52.
42. Farasat S., Aksentijevich I., Toro J.R. Autoinflammatory diseases: clinical and genetic advances. Arch. Dermatol. 2008, 144:392-402.
43. Furst D.E., Keystone E.C., Kirkham B., Kavanaugh A., Fleischmann R., Mease P., Breedveld F.C., Smolen J.S., Kalden J.R., Burmester G.R., Braun J., Emery P., Winthrop K., Bresnihan B., De Benedetti F., Dorner T., Gibofsky A., Schiff M.H., Sieper J., Singer N., Van Riel P.L., Weinblatt M.E., Weisman M.H. Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2008. Ann. Rheum. Dis. 2008, 67(Suppl 3):iii2-iii25.
44. Gaestel M., Kotlyarov A., Kracht M. Targeting innate immunity protein kinase signalling in inflammation. Nat. Rev. Drug Discov. 2009, 8:480-499.
45. Geng H., Wittwer T., Dittrich-Breiholz O., Kracht M., Schmitz M.L. Phosphorylation of NF-kappaB p65 at Ser468 controls its COMMD1-dependent ubiquitination and target gene-specific proteasomal elimination. EMBO Rep. 2009, 10:381-386.
46. Gosset M., Pigenet A., Salvat C., Berenbaum F., Jacques C. Inhibition of matrix metalloproteinase-3 and -13 synthesis induced by IL-1{beta} in chondrocytes from mice lacking microsomal prostaglandin E synthase-1. J. Immunol. 2010, 185:6244-6252.
47. Granowitz E.V., Clark B.D., Vannier E., Callahan M.V., Dinarello C.A. Effect of interleukin-1 (IL-1) blockade on cytokine synthesis: I. IL-1 receptor antagonist inhibits IL-1-induced cytokine synthesis and blocks the binding of IL-1 to its type II receptor on human monocytes. Blood 1992, 79:2356-2363.
48. Graudal N., Jurgens G. Similar effects of disease-modifying antirheumatic drugs, glucocorticoids, and biologic agents on radiographic progression in rheumatoid arthritis: meta-analysis of 70 randomized placebo-controlled or drug-controlled studies, including 112 comparisons. Arthritis Rheum. 2010, 62:2852-2863.
49. Grivennikov S.I., Greten F.R., Karin M. Immunity, inflammation, and cancer. Cell 2010, 140:883-899.
50. Grunhagen D.J., de Wilt J.H., ten Hagen T.L., Eggermont A.M. Technology insight: Utility of TNF-alpha-based isolated limb perfusion to avoid amputation of irresectable tumors of the extremities. Nat. Clin. Pract. Oncol. 2006, 3:94-103.
51. Guo L., Wei G., Zhu J., Liao W., Leonard W.J., Zhao K., Paul W. IL-1 family members and STAT activators induce cytokine production by Th2, Th17, and Th1 cells. Proc. Natl. Acad. Sci. U.S.A. 2009, 106:13463-13468.
52. Hitti E., Iakovleva T., Brook M., Deppenmeier S., Gruber A.D., Radzioch D., Clark A.R., Blackshear P.J., Kotlyarov A., Gaestel M. Mitogen-activated protein kinase-activated protein kinase 2 regulates tumor necrosis factor mRNA stability and translation mainly by altering tristetraprolin expression, stability, and binding to adenine/uridine-rich element. Mol. Cell. Biol. 2006, 26:2399-2407.
53. Hoffmann A., Levchenko A., Scott M.L., Baltimore D. The IkappaB-NF-kappaB signaling module: temporal control and selective gene activation. Science 2002, 298:1241-1245.
54. Hoffmann E., Dittrich-Breiholz O., Holtmann H., Kracht M. Multiple control of interleukin-8 gene expression. J. Leukoc. Biol. 2002, 72:847-855.
55. Horn T., Sandmann T., Fischer B., Axelsson E., Huber W., Boutros M. Mapping of signaling networks through synthetic genetic interaction analysis by RNAi. Nat. Methods 2011.
56. Hubbard L.L., Ballinger M.N., Thomas P.E., Wilke C.A., Standiford T.J., Kobayashi K.S., Flavell R.A., Moore B.B. A role for IL-1 receptor-associated kinase-M in prostaglandin E(2)-induced immunosuppression post-bone marrow transplantation. J. Immunol. 2010, 184:6299-6308.
57. Hyduke D.R., Palsson B.O. Towards genome-scale signalling-network reconstructions. Nat. Rev. Genet. 2010, 11:297-307.
58. Inokuchi S., Aoyama T., Miura K., Osterreicher C.H., Kodama Y., Miyai K., Akira S., Brenner D.A., Seki E. Disruption of TAK1 in hepatocytes causes hepatic injury, inflammation, fibrosis, and carcinogenesis. Proc. Natl. Acad. Sci. U.S.A. 2010, 107:844-849.
59. Janes K.A., Albeck J.G., Gaudet S., Sorger P.K., Lauffenburger D.A., Yaffe M.B. A systems model of signaling identifies a molecular basis set for cytokine-induced apoptosis. Science 2005, 310:1646-1653.
60. Janes K.A., Gaudet S., Albeck J.G., Nielsen U.B., Lauffenburger D.A., Sorger P.K. The response of human epithelial cells to TNF involves an inducible autocrine cascade. Cell 2006, 124:1225-1239.
61. Janes K.A., Reinhardt H.C., Yaffe M.B. Cytokine-induced signaling networks prioritize dynamic range over signal strength. Cell 2008, 135:343-354.
62. Jeffrey K.L., Camps M., Rommel C., Mackay C.R. Targeting dual-specificity phosphatases: manipulating MAP kinase signalling and immune responses. Nat. Rev. Drug Discov. 2007, 6:391-403.
63. Kajino T., Ren H., Iemura S., Natsume T., Stefansson B., Brautigan D.L., Matsumoto K., Ninomiya-Tsuji J. Protein phosphatase 6 down-regulates TAK1 kinase activation in the IL-1 signaling pathway. J. Biol. Chem. 2006, 281:39891-39896.
64. Kassel O., Sancono A., Kratzschmar J., Kreft B., Stassen M., Cato A.C. Glucocorticoids inhibit MAP kinase via increased expression and decreased degradation of MKP-1. EMBO J. 2001, 20:7108-7116.
65. Kelder T., Pico A.R., Hanspers K., van Iersel M.P., Evelo C., Conklin B.R. Mining biological pathways using WikiPathways web services. PLoS One 2009, 4:e6447.
66. Keller M., Mazuch J., Abraham U., Eom G.D., Herzog E.D., Volk H.D., Kramer A., Maier B. A circadian clock in macrophages controls inflammatory immune responses. Proc. Natl. Acad. Sci. U.S.A. 2009, 106:21407-21412.
67. Kim S.H., Han S.Y., Azam T., Yoon D.Y., Dinarello C.A. Interleukin-32: a cytokine and inducer of TNFalpha. Immunity 2005, 22:131-142.
68. Klamt S., Saez-Rodriguez J., Gilles E.D. Structural and functional analysis of cellular networks with Cell NetAnalyzer. BMC Syst. Biol. 2007, 1:2.
69. Klamt S., Saez-Rodriguez J., Lindquist J.A., Simeoni L., Gilles E.D. A methodology for the structural and functional analysis of signaling and regulatory networks. BMC Bioinformatics 2006, 7:56.
70. Klatt A.R., Klinger G., Paul-Klausch B., Renno J.H., Schmidt J., Malchau G., Wielckens K. TAK1 mediates the collagen-II-dependent induction of the COX-2 gene and PGE2 release in primary human chondrocytes. Connect. Tissue Res. 2010, 51:452-458.
71. Kopf M., Bachmann M.F., Marsland B.J. Averting inflammation by targeting the cytokine environment. Nat. Rev. Drug Discov. 2010, 9:703-718.
72. Kovalenko A., Chable-Bessia C., Cantarella G., Israel A., Wallach D., Courtois G. The tumour suppressor CYLD negatively regulates NF-kappaB signalling by deubiquitination. Nature 2003, 424:801-805.
73. Kracht M., Saklatvala J. Transcriptional and post-transcriptional control of gene expression in inflammation. Cytokine 2002, 20:91-106.
74. Lai W.S., Parker J.S., Grissom S.F., Stumpo D.J., Blackshear P.J. Novel mRNA targets for tristetraprolin (TTP) identified by global analysis of stabilized transcripts in TTP-deficient fibroblasts. Mol. Cell. Biol. 2006, 26:9196-9208.
75. Laplantine E., Fontan E., Chiaravalli J., Lopez T., Lakisic G., Veron M., Agou F., Israel A. NEMO specifically recognizes K63-linked poly-ubiquitin chains through a new bipartite ubiquitin-binding domain. EMBO J. 2009, 28:2885-2895.
76. Larsen C.M., Faulenbach M., Vaag A., Volund A., Ehses J.A., Seifert B., Mandrup-Poulsen T., Donath M.Y. Interleukin-1-receptor antagonist in type 2 diabetes mellitus. N. Engl. J. Med. 2007, 356:1517-1526.
77. Li F., Thiele I., Jamshidi N., Palsson B.O. Identification of potential pathway mediation targets in Toll-like receptor signaling. PLoS Comput. Biol. 2009, 5:e1000292.
78. Liang J., Lei T., Song Y., Yanes N., Qi Y., Fu M. RNA-destabilizing factor tristetraprolin negatively regulates NF-kappaB signaling. J. Biol. Chem. 2009, 284:29383-29390.
79. Liu Y., Shepherd E.G., Nelin L.D. MAPK phosphatases-regulating the immune response. Nat. Rev. Immunol. 2007, 7:202-212.
80. Lomedico P.T., Gubler U., Hellmann C.P., Dukovich M., Giri J.G., Pan Y.C., Collier K., Semionow R., Chua A.O., Mizel S.B. Cloning and expression of murine interleukin-1 cDNA in Escherichia coli. Nature 1984, 312:458-462.
81. Luster A.D., Alon R., von Andrian U.H. Immune cell migration in inflammation: present and future therapeutic targets. Nat. Immunol. 2005, 6:1182-1190.
82. Mahtani K.R., Brook M., Dean J.L., Sully G., Saklatvala J., Clark A.R. Mitogen-activated protein kinase p38 controls the expression and posttranslational modification of tristetraprolin, a regulator of tumor necrosis factor alpha mRNA stability. Mol. Cell. Biol. 2001, 21:6461-6469.
83. Manna S.K., Ramesh G.T. Interleukin-8 induces nuclear transcription factor-kappaB through a TRAF6-dependent pathway. J. Biol. Chem. 2005, 280:7010-7021.
84. Martin M.U., Falk W. The interleukin-1 receptor complex and interleukin-1 signal transduction. Eur. Cytokine Netw. 1997, 8:5-17.
85. Martinon F., Burns K., Tschopp J. The inflammasome: a molecular platform triggering activation of inflammatory caspases and processing of proIL-beta. Mol. Cell 2002, 10:417-426.
86. Martinon F., Mayor A., Tschopp J. The inflammasomes: guardians of the body. Annu. Rev. Immunol. 2009, 27:229-265.
87. McDonald B., Pittman K., Menezes G.B., Hirota S.A., Slaba I., Waterhouse C.C., Beck P.L., Muruve D.A., Kubes P. Intravascular danger signals guide neutrophils to sites of sterile inflammation. Science 2010, 330:362-366.
88. Medzhitov R. Inflammation 2010: new adventures of an old flame. Cell 2010, 140:771-776.
89. Medzhitov R., Horng T. Transcriptional control of the inflammatory response. Nat. Rev. Immunol. 2009, 9:692-703.
90. Mendoza H., Campbell D.G., Burness K., Hastie J., Ronkina N., Shim J.H., Arthur J.S., Davis R.J., Gaestel M., Johnson G.L., Ghosh S., Cohen P. Roles for TAB1 in regulating the IL-1-dependent phosphorylation of the TAB3 regulatory subunit and activity of the TAK1 complex. Biochem. J. 2008, 409:711-722.
91. Metzker M.L. Sequencing technologies-the next generation. Nat. Rev. Genet. 2010, 11:31-46.
92. Nathan C. Points of control in inflammation. Nature 2002, 420:846-852.
93. Nathan C., Ding A. Nonresolving inflammation. Cell 2010, 140:871-882.
94. Nemunaitis J., Appelbaum F.R., Lilleby K., Buhles W.C., Rosenfeld C., Zeigler Z.R., Shadduck R.K., Singer J.W., Meyer W., Buckner C.D. Phase I study of recombinant interleukin-1 beta in patients undergoing autologous bone marrow transplant for acute myelogenous leukemia. Blood 1994, 83:3473-3479.
95. Ninomiya-Tsuji J., Kishimoto K., Hiyama A., Inoue J., Cao Z., Matsumoto K. The kinase TAK1 can activate the NIK-I kappaB as well as the MAP kinase cascade in the IL-1 signalling pathway. Nature 1999, 398:252-256.
96. Nold M.F., Nold-Petry C.A., Zepp J.A., Palmer B.E., Bufler P., Dinarello C.A. IL-37 is a fundamental inhibitor of innate immunity. Nat. Immunol. 2010, 11:1014-1022.
97. O'Neill L.A. Targeting signal transduction as a strategy to treat inflammatory diseases. Nat. Rev. Drug Discov. 2006, 5:549-563.
98. O'Shea J.M., Perkins N.D. Regulation of the RelA (p65) transactivation domain. Biochem. Soc. Trans. 2008, 36:603-608.
99. Oda K., Kitano H. A comprehensive map of the toll-like receptor signaling network. Mol. Syst. Biol. 2006, 2:2006.
100. Osborne R. Fresh from the biologic pipeline. Nat. Biotechnol. 2009, 27:222-225.
101. Papin J.A., Hunter T., Palsson B.O., Subramaniam S. Reconstruction of cellular signalling networks and analysis of their properties. Nat. Rev. Mol. Cell Biol. 2005, 6:99-111.
102. Papin J.A., Palsson B.O. The JAK-STAT signaling network in the human B-cell: an extreme signaling pathway analysis. Biophys. J. 2004, 87:37-46.
103. Papin J.A., Palsson B.O. Topological analysis of mass-balanced signaling networks: a framework to obtain network properties including crosstalk. J. Theor. Biol. 2004, 227:283-297.
104. Pico A.R., Kelder T., van Iersel M.P., Hanspers K., Conklin B.R., Evelo C. WikiPathways: pathway editing for the people. PLoS Biol. 2008, 6:e184.
105. Rao P., Hayden M.S., Long M., Scott M.L., West A.P., Zhang D., Oeckinghaus A., Lynch C., Hoffmann A., Baltimore D., Ghosh S. IkappaBbeta acts to inhibit and activate gene expression during the inflammatory response. Nature 2010, 466:1115-1119.
106. Reddy S., Jia S., Geoffrey R., Lorier R., Suchi M., Broeckel U., Hessner M.J., Verbsky J. An autoinflammatory disease due to homozygous deletion of the IL1RN locus. N. Engl. J. Med. 2009, 360:2438-2444.
107. Renner F., Schmitz M.L. Autoregulatory feedback loops terminating the NF-kappaB response. Trends Biochem. Sci. 2009, 34:128-135.
108. Rothgiesser K.M., Fey M., Hottiger M.O. Acetylation of p65 at lysine 314 is important for late NF-kappaB-dependent gene expression. BMC Genomics 2010, 11:22.
109. Ryan J.G., Goldbach-Mansky R. The spectrum of autoinflammatory diseases: recent bench to bedside observations. Curr. Opin. Rheumatol. 2008, 20:66-75.
110. Saag K.G., Teng G.G., Patkar N.M., Anuntiyo J., Finney C., Curtis J.R., Paulus H.E., Mudano A., Pisu M., Elkins-Melton M., Outman R., Allison J.J., Suarez A.M., Bridges S.L., Chatham W.W., Hochberg M., MacLean C., Mikuls T., Moreland L.W., O'Dell J., Turkiewicz A.M., Furst D.E. American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis. Arthritis Rheum. 2008, 59:762-784.
111. Saez-Rodriguez J., Simeoni L., Lindquist J.A., Hemenway R., Bommhardt U., Arndt B., Haus U.U., Weismantel R., Gilles E.D., Klamt S., Schraven B. A logical model provides insights into T cell receptor signaling. PLoS Comput. Biol. 2007, 3:e163.
112. Salliot C., Dougados M., Gossec L. Risk of serious infections during rituximab, abatacept and anakinra therapies for rheumatoid arthritis: meta-analyses of randomized placebo-controlled trials. Ann. Rheum. Dis. 2008.
113. Sato S., Sanjo H., Takeda K., Ninomiya-Tsuji J., Yamamoto M., Kawai T., Matsumoto K., Takeuchi O., Akira S. Essential function for the kinase TAK1 in innate and adaptive immune responses. Nat. Immunol. 2005, 6:1087-1095.
114. Sato S., Sanjo H., Tsujimura T., Ninomiya-Tsuji J., Yamamoto M., Kawai T., Takeuchi O., Akira S. TAK1 is indispensable for development of T cells and prevention of colitis by the generation of regulatory T cells. Int. Immunol. 2006, 18:1405-1411.
115. Scheinecker C., Smolen J., Yasothan U., Stoll J., Kirkpatrick P. Tocilizumab. Nat. Rev. Drug Discov. 2009, 8:273-274.
116. Schichl Y.M., Resch U., Hofer-Warbinek R., de M.R. Tristetraprolin impairs NF-kappaB/p65 nuclear translocation. J. Biol. Chem. 2009, 284:29571-29581.
117. Schiller J.H., Storer B.E., Witt P.L., Alberti D., Tombes M.B., Arzoomanian R., Proctor R.A., McCarthy D., Brown R.R., Voss S.D. Biological and clinical effects of intravenous tumor necrosis factor-alpha administered three times weekly. Cancer Res. 1991, 51:1651-1658.
118. Schmidt-Supprian M., Bloch W., Courtois G., Addicks K., Israel A., Rajewsky K., Pasparakis M. NEMO/IKK gamma-deficient mice model incontinentia pigmenti. Mol. Cell 2000, 5:981-992.
119. Schmitz J., Owyang A., Oldham E., Song Y., Murphy E., McClanahan T.K., Zurawski G., Moshrefi M., Qin J., Li X., Gorman D.M., Bazan J.F., Kastelein R.A. IL-33, an interleukin-1-like cytokine that signals via the IL-1 receptor-related protein ST2 and induces T helper type 2-associated cytokines. Immunity 2005, 23:479-490.
120. Shembade N., Ma A., Harhaj E.W. Inhibition of NF-kappaB signaling by A20 through disruption of ubiquitin enzyme complexes. Science 2010, 327:1135-1139.
121. Shim J.H., Xiao C., Paschal A.E., Bailey S.T., Rao P., Hayden M.S., Lee K.Y., Bussey C., Steckel M., Tanaka N., Yamada G., Akira S., Matsumoto K., Ghosh S. TAK1, but not TAB1 or TAB2, plays an essential role in multiple signaling pathways in vivo. Genes Dev. 2005, 19:2668-2681.
122. Shoval O., Alon U. SnapShot: network motifs. Cell 2010, 143:326-3e1.
123. Sims J.E., March C.J., Cosman D., Widmer M.B., MacDonald H.R., McMahan C.J., Grubin C.E., Wignall J.M., Jackson J.L., Call S.M. cDNA expression cloning of the IL-1 receptor, a member of the immunoglobulin superfamily. Science 1988, 241:585-589.
124. Sims J.E., Smith D.E. The IL-1 family: regulators of immunity. Nat. Rev. Immunol. 2010, 10:89-102.
125. Smith J.W., Urba W.J., Curti B.D., Elwood L.J., Steis R.G., Janik J.E., Sharfman W.H., Miller L.L., Fenton R.G., Conlon K.C. The toxic and hematologic effects of interleukin-1 alpha administered in a phase I trial to patients with advanced malignancies. J. Clin. Oncol. 1992, 10:1141-1152.
126. So A., De Smedt T., Revaz S., Tschopp J. A pilot study of IL-1 inhibition by anakinra in acute gout. Arthritis Res. Ther. 2007, 9:R28.
127. Solt L.A., Madge L.A., May M.J. NEMO-binding domains of both IKKalpha and IKKbeta regulate IkappaB kinase complex assembly and classical NF-kappaB activation. J. Biol. Chem. 2009, 284:27596-27608.
128. Solt L.A., Madge L.A., Orange J.S., May M.J. Interleukin-1-induced NF-kappaB activation is NEMO-dependent but does not require IKKbeta. J. Biol. Chem. 2007, 282:8724-8733.
129. Stoll J.G., Yasothan U. Rheumatoid arthritis market. Nat. Rev. Drug Discov. 2009, 8:693-694.
130. Strand V., Kimberly R., Isaacs J.D. Biologic therapies in rheumatology: lessons learned, future directions. Nat. Rev. Drug Discov. 2007, 6:75-92.
131. Sun S.C., Ganchi P.A., Ballard D.W., Greene W.C. NF-kappa B controls expression of inhibitor I kappa B alpha: evidence for an inducible autoregulatory pathway. Science 1993, 259:1912-1915.
132. Takaesu G., Kishida S., Hiyama A., Yamaguchi K., Shibuya H., Irie K., Ninomiya-Tsuji J., Matsumoto K. TAB2, a novel adaptor protein, mediates activation of TAK1 MAPKKK by linking TAK1 to TRAF6 in the IL-1 signal transduction pathway. Mol. Cell 2000, 5:649-658.
133. Takeuchi O., Akira S. Pattern recognition receptors and inflammation. Cell 2010, 140:805-820.
134. Tanaka T., Grusby M.J., Kaisho T. PDLIM2-mediated termination of transcription factor NF-kappaB activation by intranuclear sequestration and degradation of the p65 subunit. Nat. Immunol. 2007, 8:584-591.
135. Taylor G.A., Carballo E., Lee D.M., Lai W.S., Thompson M.J., Patel D.D., Schenkman D.I., Gilkeson G.S., Broxmeyer H.E., Haynes B.F., Blackshear P.J. A pathogenetic role for TNF alpha in the syndrome of cachexia, arthritis, and autoimmunity resulting from tristetraprolin (TTP) deficiency. Immunity 1996, 4:445-454.
136. Terkeltaub R., Sundy J.S., Schumacher H.R., Murphy F., Bookbinder S., Biedermann S., Wu R., Mellis S., Radin A. The interleukin 1 inhibitor rilonacept in treatment of chronic gouty arthritis: results of a placebo-controlled, monosequence crossover, non-randomised, single-blind pilot study. Ann. Rheum. Dis. 2009, 68:1613-1617.
137. Teschendorff A.E., Gomez S., Arenas A., El-Ashry D., Schmidt M., Gehrmann M., Caldas C. Improved prognostic classification of breast cancer defined by antagonistic activation patterns of immune response pathway modules. BMC Cancer 2010, 10:604.
138. Thiefes A., Wolf A., Doerrie A., Grassl G.A., Matsumoto K., Autenrieth I., Bohn E., Sakurai H., Niedenthal R., Resch K., Kracht M. The Yersinia enterocolitica effector YopP inhibits host cell signalling by inactivating the protein kinase TAK1 in the IL-1 signalling pathway. EMBO Rep. 2006, 7:838-844.
139. Tokunaga F., Sakata S., Saeki Y., Satomi Y., Kirisako T., Kamei K., Nakagawa T., Kato M., Murata S., Yamaoka S., Yamamoto M., Akira S., Takao T., Tanaka K., Iwai K. Involvement of linear polyubiquitylation of NEMO in NF-kappaB activation. Nat. Cell Biol. 2009, 11:123-132.
140. Treffkorn L., Scheibe R., Maruyama T., Dieter P. PGE2 exerts its effect on the LPS-induced release of TNF-alpha, ET-1, IL-1alpha, IL-6 and IL-10 via the EP2 and EP4 receptor in rat liver macrophages. Prostaglandins Other Lipid Mediat. 2004, 74:113-123.
141. Trompouki E., Hatzivassiliou E., Tsichritzis T., Farmer H., Ashworth A., Mosialos G. CYLD is a deubiquitinating enzyme that negatively regulates NF-kappaB activation by TNFR family members. Nature 2003, 424:793-796.
142. Uemura N., Kajino T., Sanjo H., Sato S., Akira S., Matsumoto K., Ninomiya-Tsuji J. TAK1 is a component of the Epstein-Barr virus LMP1 complex and is essential for activation of JNK but not of NF-kappaB. J. Biol. Chem. 2006, 281:7863-7872.
143. van Iersel M.P., Kelder T., Pico A.R., Hanspers K., Coort S., Conklin B.R., Evelo C. Presenting and exploring biological pathways with PathVisio. BMC Bioinformatics 2008, 9:399.
144. Vereecke L., Beyaert R., van Loo G. The ubiquitin-editing enzyme A20 (TNFAIP3) is a central regulator of immunopathology. Trends Immunol. 2009, 30:383-391.
145. Vilcek J., Feldmann M. Historical review: cytokines as therapeutics and targets of therapeutics. Trends Pharmacol. Sci. 2004, 25:201-209.
146. Wall E.A., Zavzavadjian J.R., Chang M.S., Randhawa B., Zhu X., Hsueh R.C., Liu J., Driver A., Bao X.R., Sternweis P.C., Simon M.I., Fraser I.D. Suppression of LPS-induced TNF-alpha production in macrophages by cAMP is mediated by PKA-AKAP95-p105. Sci. Signal. 2009, 2:ra28.
147. Walsh M.C., Kim G.K., Maurizio P.L., Molnar E.E., Choi Y. TRAF6 autoubiquitination-independent activation of the NFkappaB and MAPK pathways in response to IL-1 and RANKL. PLoS One 2008, 3:e4064.
148. Wan J., Zhang W., Wu L., Bai T., Zhang M., Lo K.W., Chui Y.L., Cui Y., Tao Q., Yamamoto M., Akira S., Wu Z. BS69, a specific adaptor in the latent membrane protein 1-mediated c-Jun N-terminal kinase pathway. Mol. Cell. Biol. 2006, 26:448-456.
149. Wang C., Deng L., Hong M., Akkaraju G.R., Inoue J., Chen Z.J. TAK1 is a ubiquitin-dependent kinase of MKK and IKK. Nature 2001, 412:346-351.
150. Waugh D.J., Wilson C. The interleukin-8 pathway in cancer. Clin. Cancer Res. 2008, 14:6735-6741.
151. Weber A., Wasiliew P., Kracht M. Interleukin-1 (IL-1) pathway. Sci. Signal. 2010, 3:cm1.
152. Windheim M., Stafford M., Peggie M., Cohen P. Interleukin-1 (IL-1) induces the Lys63-linked polyubiquitination of IL-1 receptor-associated kinase 1 to facilitate NEMO binding and the activation of IkappaBalpha kinase. Mol. Cell. Biol. 2008, 28:1783-1791.
153. Wu X., Sun S.C. Retroviral oncoprotein Tax deregulates NF-kappaB by activating Tak1 and mediating the physical association of Tak1-IKK. EMBO Rep. 2007, 8:510-515.
154. Xu D., Jiang H.R., Kewin P., Li Y., Mu R., Fraser A.R., Pitman N., Kurowska-Stolarska M., McKenzie A.N., McInnes I.B., Liew F.Y. IL-33 exacerbates antigen-induced arthritis by activating mast cells. Proc. Natl. Acad. Sci. U.S.A. 2008, 105:10913-10918.
155. Yamauchi S., Ito H., Miyajima A. IkappaBeta, a nuclear IkappaB protein, positively regulates the NF-kappaB-mediated expression of proinflammatory cytokines. Proc. Natl. Acad. Sci. U.S.A. 2010, 107:11924-11929.
156. Yamazaki K., Gohda J., Kanayama A., Miyamoto Y., Sakurai H., Yamamoto M., Akira S., Hayashi H., Su B., Inoue J. Two mechanistically and temporally distinct NF-kappaB activation pathways in IL-1 signaling. Sci. Signal. 2009, 2:ra66.
157. Yang S.K., Wang Y.C., Chao C.C., Chuang Y.J., Lan C.Y., Chen B.S. Dynamic cross-talk analysis among TNF-R, TLR-4 and IL-1R signalings in TNFalpha-induced inflammatory responses. BMC Med. Genomics 2010, 3:19.
158. Yarilina A., Park-Min K.H., Antoniv T., Hu X., Ivashkiv L.B. TNF activates an IRF1-dependent autocrine loop leading to sustained expression of chemokines and STAT1-dependent type I interferon-response genes. Nat. Immunol. 2008, 9:378-387.
159. Yen H., Ooka T., Iguchi A., Hayashi T., Sugimoto N., Tobe T. NleC, a type III secretion protease, compromises NF-kappaB activation by targeting p65/RelA. PLoS Pathog. 2010, 6:e1001231.
160. Yu Y., Ge N., Xie M., Sun W., Burlingame S., Pass A.K., Nuchtern J.G., Zhang D., Fu S., Schneider M.D., Fan J., Yang J. Phosphorylation of Thr-178 and Thr-184 in the TAK1 T-loop is required for interleukin (IL)-1-mediated optimal NFkappaB and AP-1 activation as well as IL-6 gene expression. J. Biol. Chem. 2008, 283:24497-24505.
161. Zhao Q., Wang X., Nelin L.D., Yao Y., Matta R., Manson M.E., Baliga R.S., Meng X., Smith C.V., Bauer J.A., Chang C.H., Liu Y. MAP kinase phosphatase 1 controls innate immune responses and suppresses endotoxic shock. J. Exp. Med. 2006, 203:131-140.